Dynavax Technologies (NASDAQ: DVAX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Dynavax Technologies Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Dynavax Technologies Company Info
A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.
News & Analysis
One pundit believes the share price could more than double.
The company delivered resounding beats on both the top and bottom lines in the second quarter.
Its partner's coronavirus vaccine comes one important step closer to approval in Europe.
One of its vaccine partners had some encouraging regulatory news to report.
The company earns an Emergency Use Authorization from a well-off Middle Eastern country.
Several coronavirus vaccines using the company's adjuvant are advancing up the regulatory ladder.
Investors weren't inspired by the bitoech's mixed Q4.
One analyst gets notably more bullish on the biotech's shares.
DVAX earnings call for the period ending December 31, 2022.
DVAX earnings call for the period ending September 30, 2022.
DVAX earnings call for the period ending June 30, 2022.
DVAX earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.